IRIS
CONTE, BENEDETTA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 1.063
NA - Nord America 866
EU - Europa 719
SA - Sud America 101
AF - Africa 93
OC - Oceania 2
Totale 2.844
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 825
SG - Singapore 452
RU - Federazione Russa 371
CN - Cina 176
HK - Hong Kong 174
VN - Vietnam 103
IT - Italia 92
ES - Italia 72
BR - Brasile 68
BJ - Benin 59
DE - Germania 52
BD - Bangladesh 43
KR - Corea 40
FR - Francia 34
CA - Canada 27
AT - Austria 22
IN - India 19
UA - Ucraina 17
ZA - Sudafrica 16
AR - Argentina 14
PL - Polonia 12
GB - Regno Unito 11
FI - Finlandia 10
JP - Giappone 9
IQ - Iraq 8
NL - Olanda 8
MX - Messico 6
VE - Venezuela 6
JM - Giamaica 5
EC - Ecuador 4
SE - Svezia 4
TN - Tunisia 4
AE - Emirati Arabi Uniti 3
CL - Cile 3
CO - Colombia 3
ID - Indonesia 3
LB - Libano 3
PH - Filippine 3
PY - Paraguay 3
SY - Repubblica araba siriana 3
TR - Turchia 3
AU - Australia 2
BE - Belgio 2
CZ - Repubblica Ceca 2
DZ - Algeria 2
IL - Israele 2
KE - Kenya 2
KG - Kirghizistan 2
LT - Lituania 2
NP - Nepal 2
PK - Pakistan 2
PS - Palestinian Territory 2
TH - Thailandia 2
TW - Taiwan 2
AL - Albania 1
AM - Armenia 1
AO - Angola 1
AZ - Azerbaigian 1
BA - Bosnia-Erzegovina 1
BF - Burkina Faso 1
BS - Bahamas 1
BY - Bielorussia 1
CI - Costa d'Avorio 1
EG - Egitto 1
GA - Gabon 1
GM - Gambi 1
GR - Grecia 1
HU - Ungheria 1
JO - Giordania 1
KZ - Kazakistan 1
MA - Marocco 1
MD - Moldavia 1
ML - Mali 1
MN - Mongolia 1
MW - Malawi 1
NG - Nigeria 1
OM - Oman 1
PR - Porto Rico 1
RO - Romania 1
SI - Slovenia 1
TT - Trinidad e Tobago 1
UZ - Uzbekistan 1
Totale 2.844
Salva come PNG Salva come JPEG
Città #
San Jose 247
Singapore 192
Hong Kong 173
Council Bluffs 87
Ashburn 86
Los Angeles 78
Cotonou 59
Moscow 43
Beijing 39
Seoul 38
Ho Chi Minh City 35
Lauterbourg 33
Buffalo 29
New York 26
Hanoi 21
Assago 20
Santa Clara 18
St Louis 18
Falkenstein 16
Columbus 15
Nuremberg 12
Chennai 10
Dallas 10
Helsinki 10
Vienna 10
Chicago 9
Munich 9
Orem 9
Redondo Beach 9
Da Nang 8
Johannesburg 8
Toronto 8
Warsaw 8
Shanghai 7
São Paulo 7
Tokyo 7
Frankfurt am Main 6
Guangzhou 6
Milan 6
Montreal 6
Novara 6
Tianjin 6
Boston 5
Brembate di Sopra 5
Hải Dương 5
Kyiv 5
San Francisco 5
Atlanta 4
Denver 4
Haiphong 4
Kingston 4
Mumbai 4
Tornaco 4
Amsterdam 3
Barcelona 3
Belo Horizonte 3
Brooklyn 3
Buenos Aires 3
Caracas 3
Charlotte 3
Curitiba 3
Houston 3
Mexico City 3
Ottawa 3
Phoenix 3
Phủ Lý 3
Poplar 3
Rio de Janeiro 3
Rome 3
Santiago 3
Seattle 3
Stockholm 3
Venice 3
Asunción 2
Baghdad 2
Baie-D'Urfé 2
Barnet 2
Bishkek 2
Camaiore 2
Cape Town 2
Carapicuíba 2
Changzhou 2
Cleveland 2
Dalian 2
Damascus 2
Galliate 2
Genoa 2
Guarulhos 2
Istanbul 2
Katowice 2
Manchester 2
Marcos Paz 2
Matino 2
Nairobi 2
Naples 2
Parauapebas 2
Prague 2
Quito 2
Quận Ba 2
Sarno 2
Totale 1.613
Salva come PNG Salva come JPEG
Nome #
TNBC-DX genomic test in early-stage triple-negative breast cancer treated with neoadjuvant taxane-based therapy 113
Frequency and spectrum of PIK3CA somatic mutations in breast cancer 108
Circulating tumor DNA dynamics in advanced breast cancer treated with CDK4/6 inhibition and endocrine therapy 95
Effect of dose-dense adjuvant chemotherapy in hormone receptor positive/HER2-negative early breast cancer patients according to immunohistochemically defined luminal subtype: an exploratory analysis of the GIM2 trial 93
Dose-dense adjuvant chemotherapy in early breast cancer patients: 15-year results of the Phase 3 Mammella InterGruppo (MIG)-1 study 93
De novo Metastatic Breast Cancer Arising in Young Women: Review of the Current Evidence 89
Dose-dense adjuvant chemotherapy in HER2-positive early breast cancer patients before and after the introduction of trastuzumab: Exploratory analysis of the GIM2 trial 86
A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation 85
Development and validation of the new HER2DX assay for predicting pathological response and survival outcome in early-stage HER2-positive breast cancer 83
A 14-gene B-cell immune signature in early-stage triple-negative breast cancer (TNBC): a pooled analysis of seven studies 79
Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer 77
Efficacy of adjuvant chemotherapy schedules for breast cancer according to body mass index: results from the phase III GIM2 trial 76
Sex Hormones and Hormone Therapy during COVID-19 Pandemic: Implications for Patients with Cancer 74
SNPs of aromatase predict long-term survival and aromatase inhibitor toxicity in patients with early breast cancer: a biomarker analysis of the GIM4 and GIM5 trials 73
Endocrine-Based Treatments in Clinically-Relevant Subgroups of Hormone Receptor-Positive/HER2-Negative Metastatic Breast Cancer: Systematic Review and Meta-Analysis 71
HER2DX ERBB2 mRNA expression in advanced HER2-positive breast cancer treated with T-DM1 70
Adding a platinum agent to neoadjuvant chemotherapy for triple-negative breast cancer: the end of the debate 69
Breast Cancer Surgery in the COVID-19 Pandemic: Validation of a Preventive Program for Patients and Health Care Workers 66
Gonadotropin-releasing hormone analogues for the prevention of chemotherapy-induced premature ovarian failure in breast cancer patients 65
Treatment-induced early menopause and the protective role of gonadotropin-releasing hormone agonists during chemotherapy 64
Update on the management of breast cancer during pregnancy 63
Anthracycline, taxane, and trastuzumab-based neoadjuvant chemotherapy in HER2-positive early breast cancer: phase II trial 63
Independent Validation of the PAM50-Based Chemo-Endocrine Score (CES) in Hormone Receptor-Positive HER2-Positive Breast Cancer Treated with Neoadjuvant Anti-HER2-Based Therapy 57
HER2-enriched subtype and pathological complete response in HER2-positive breast cancer: A systematic review and meta-analysis 56
T-DM1 versus pertuzumab, trastuzumab and a taxane as first-line therapy of early-relapsed HER2-positive metastatic breast cancer: an Italian multicenter observational study 54
Prospective study to optimize care and improve knowledge on ovarian function and/or fertility preservation in young breast cancer patients: Results of the pilot phase of the PREgnancy and FERtility (PREFER) study 53
T-DM1 Efficacy in Patients With HER2-positive Metastatic Breast Cancer Progressing After a Taxane Plus Pertuzumab and Trastuzumab: An Italian Multicenter Observational Study 53
Italian survey on managing immune checkpoint inhibitors in oncology during COVID-19 outbreak 52
Intrinsic subtypes and therapeutic decision-making in hormone receptor-positive/HER2-negative metastatic breast cancer with visceral crisis: A case report. 52
Treatment-induced early menopause and the protective role of gonadotropin-releasing hormone agonists during chemotherapy 49
Inclusion of Platinum Agents in Neoadjuvant Chemotherapy Regimens for Triple-Negative Breast Cancer Patients: Development of GRADE (Grades of Recommendation, Assessment, Development and Evaluation) Recommendation by the Italian Association of Medical Oncology (AIOM) 49
Single-agent PARP inhibitors for the treatment of patients with BRCA-mutated HER2-negative metastatic breast cancer: a systematic review and meta-analysis 48
Gonadotropin-releasing hormone analogues for the prevention of chemotherapy-induced premature ovarian failure in breast cancer patients 48
Linking tumor immune infiltration to enhanced longevity in recurrence-free breast cancer 47
Neoadjuvant endocrine therapy for luminal breast tumors: State of the art, challenges and future perspectives 47
Potential Mechanisms of Ovarian Protection with Gonadotropin-Releasing Hormone Agonist in Breast Cancer Patients: A Review 38
Prognostic value of intrinsic subtypes in hormone-receptor-positive metastatic breast cancer: systematic review and meta-analysis 37
Potential Mechanisms of Ovarian Protection with Gonadotropin-Releasing Hormone Agonist in Breast Cancer Patients: A Review 36
Single-agent PARP inhibitors for the treatment of patients with BRCA-mutated HER2-negative metastatic breast cancer: a systematic review and meta-analysis 35
Management of young women with early breast cancer 34
Management of young women with early breast cancer 32
Inclusion of Platinum Agents in Neoadjuvant Chemotherapy Regimens for Triple-Negative Breast Cancer Patients: Development of GRADE (Grades of Recommendation, Assessment, Development and Evaluation) Recommendation by the Italian Association of Medical Oncology (AIOM) 31
Luteininzing hormone releasing hormones analogs in combination with tamoxifen for the adjuvant treatment of premenopausal women with hormone receptor positive breast cancer 27
Luteinizing hormone-releasing hormone analogs in combination with tamoxifen for the adjuvant treatment of premenopausal women with hormone receptor-positive breast cancer 25
Prospective study to optimize care and improve knowledge on ovarian function and/or fertility preservation in young breast cancer patients: Results of the pilot phase of the PREgnancy and FERtility (PREFER) study 24
Aromatase Inhibitors as Adjuvant Therapy in Early Breast Cancer: Insights into Toxicities and Their Management 23
Targeted therapies in non–small cell lung cancer and their cardiovascular impact: mechanisms, clinical profiles, and strategies of management 21
Updating the Role of Carboplatin Added to Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer: A Meta-Analysis 20
Navigating Cardiotoxicity in Immune Checkpoint Inhibitors: From Diagnosis to Long-Term Management 18
Efficacy of anti-PD1 therapy in PD1-high mRNA tumors across multiple cancer types: results from cohort 1 and cohort 2 of the phase II SOLTI-1904 ACROPOLI trial 17
Pembrolizumab and Paclitaxel in HR+/HER2- Breast Cancer with HER2-Enriched or Basal-Like Subtypes 14
Abstract PS2-10-14: Blood-based metabolomic profiling and transcriptomic analysis of circulating cd3+ t cells reveal associations with treatment response and immune activation in early breast cancer (ebc) 14
339P Transcriptomic profiling of circulating T lymphocytes predicts response to neoadjuvant therapy in patients with early breast cancer 14
Comparative efficacy between real-world and randomized studies of palbociclib+endocrine therapy in HR-positive/HER2-negative metastatic breast cancer: systematic review and meta-analysis 14
Abstract PS4-01-16: The transcriptomic profile of circulating T lymphocytes is associated with response to neoadjuvant therapy in patients with early breast cancer 13
null 6
Prevalence and clinical impact of germline pathogenic variants in breast cancer: a descriptive large single-center study 5
null 5
null 4
null 4
141P Circulating immune cells predict immunotherapy benefit in patients with triple negative breast cancer: Preliminary results from the IRIS study 3
null 2
Totale 2.936
Salva come PNG Salva come JPEG
Categoria #
all - tutte 11.584
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 11.584
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2024/2025733 0 0 0 87 28 90 63 62 171 82 25 125
2025/20262.203 108 73 151 126 284 117 327 273 217 187 218 122
Totale 2.936